MAPKAPK2 and Hyperglycemia: We have previously shown that dysregulated calcium signaling in hepatocytes in obesity activates a calcium/calmodulin-dependent protein kinase II (CaMKII)‒MK2 pathway, which then promotes hyperglycemia and insulin resistance via increasing hepatic glucose production and disrupting insulin receptor signaling [6–8].